303 related articles for article (PubMed ID: 25204479)
1. Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris.
Esmaili N; Chams-Davatchi C; Valikhani M; Daneshpazhooh M; Toosi S; Karimi A; Mortazavi H
Arch Iran Med; 2014 Sep; 17(9):626-8. PubMed ID: 25204479
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
Chams-Davatchi C; Esmaili N; Daneshpazhooh M; Valikhani M; Balighi K; Hallaji Z; Barzegari M; Akhyani M; Ghodsi SZ; Seirafi H; Nazemi MJ; Mortazavi H; Mirshams-Shahshahani M
J Am Acad Dermatol; 2007 Oct; 57(4):622-8. PubMed ID: 17583373
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial.
Mentink LF; Mackenzie MW; Tóth GG; Laseur M; Lambert FP; Veeger NJ; Cianchini G; Pavlovic MD; Jonkman MF
Arch Dermatol; 2006 May; 142(5):570-6. PubMed ID: 16702494
[TBL] [Abstract][Full Text] [Related]
6. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
[TBL] [Abstract][Full Text] [Related]
7. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
[TBL] [Abstract][Full Text] [Related]
8. [Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris].
Chams-Davatchi C; Nonahal Azar R; Daneshpazooh M; Valikhani M; Hallaji Z; Barzegari M; Firouz AR; Zakeri M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):23-5. PubMed ID: 11937925
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris.
Sharma VK; Khandpur S
Clin Exp Dermatol; 2013 Aug; 38(6):659-64. PubMed ID: 23837939
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate is effective in the treatment of pemphigus vulgaris.
Enk AH; Knop J
Arch Dermatol; 1999 Jan; 135(1):54-6. PubMed ID: 9923781
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
Sarma N; Ghosh S
Indian J Dermatol Venereol Leprol; 2007; 73(5):348-50. PubMed ID: 17921620
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial.
Dastgheib L; Sadati MS; Baghernejhad M
J Dermatolog Treat; 2015 Feb; 26(1):90-3. PubMed ID: 24552352
[TBL] [Abstract][Full Text] [Related]
14. Outcome of pemphigus vulgaris.
Kavusi S; Daneshpazhooh M; Farahani F; Abedini R; Lajevardi V; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2008 May; 22(5):580-4. PubMed ID: 18194237
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
[TBL] [Abstract][Full Text] [Related]
16. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus.
Saha M; Powell AM; Bhogal B; Black MM; Groves RW
Br J Dermatol; 2010 Apr; 162(4):790-7. PubMed ID: 19922532
[TBL] [Abstract][Full Text] [Related]
17. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris.
Chams-Davatchi C; Mortazavizadeh A; Daneshpazhooh M; Davatchi F; Balighi K; Esmaili N; Akhyani M; Hallaji Z; Seirafi H; Mortazavi H
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1285-92. PubMed ID: 23062214
[TBL] [Abstract][Full Text] [Related]
18. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study.
Rose E; Wever S; Zilliken D; Linse R; Haustein UF; Bröcker EB
J Dtsch Dermatol Ges; 2005 Mar; 3(3):200-6. PubMed ID: 16372814
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH;
Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
[TBL] [Abstract][Full Text] [Related]
20. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus.
Büsing V; Kern JS; Bruckner-Tuderman L; Hofmann SC
Dermatology; 2010; 221(2):122-6. PubMed ID: 20587990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
